Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell...

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Cancer cells exhibit high glycolysis, influencing the tumor microenvironment (TME) and promoting immune evasion.
• Immune cells in the TME can also become glycolytically activated, leading to anergy and increased immune checkpoint proteins like PD-1 and CTLA-4.

Purpose of the Study:

• To develop a nanoparticle-delivered agent for selective cancer cell glycolysis inhibition, thereby modulating the TME and enhancing anti-tumor immunity.
• To investigate the potential of targeting pyruvate dehydrogenase kinase 1 (PDK1) for tumor-specific metabolic reprogramming.

Main Methods:

• Mitochondrion-targeted nanoparticles (NPs) loaded with a dichloroacetate (DCA) prodrug were synthesized.
• The effects of these NPs on the TME, immune cell function, and tumor growth were evaluated in syngeneic mouse models.
• Combined therapy using nanoparticle-delivered DCA (Mito-DCA) and anti-PD-1 checkpoint inhibitors was assessed.

Main Results:

• Targeted NPs selectively inhibited glycolysis in tumor cells, altering the TME and increasing anti-cancer immune activation.
• Treatment led to a decrease in mean tumor volume.
• Combination therapy with Mito-DCA and anti-PD-1 resulted in an increased number of tumor-infiltrating lymphocytes.

Conclusions:

• Mitochondrion-targeted NPs delivering DCA prodrugs offer a strategy for selective cancer cell glycolysis inhibition.
• This approach can reprogram the TME, overcome immune suppression, and enhance the efficacy of cancer immunotherapy.
• Selective targeting of cancer cell metabolism presents a promising platform for improving therapeutic outcomes.